Bortezomib-based chemotherapy to treat refractory angioimmunoblastic T-cell lymphoma: A case report and review of the literature

Du,Hua‑Ping; Yang,Qian‑Qian; Zhang,Ye

doi:10.3892/ol.2016.4213

Bortezomib-based chemotherapy to treat refractory angioimmunoblastic T-cell lymphoma: A case report and review of the literature

Authors:
- Hua‑Ping Du
- Qian‑Qian Yang
- Ye Zhang
View Affiliations

Affiliations: Department of Hematology, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang 310016, P.R. China
Published online on: February 9, 2016 https://doi.org/10.3892/ol.2016.4213
Pages: 2310-2314

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The peripheral T-cell lymphomas (PTCLs) are a heterogeneous group of aggressive neoplasms that account for <15% of all non‑Hodgkin's lymphoma cases in adults. Angioimmunoblastic T-cell lymphoma (AITL) is a specific subtype of PTCL. The tumor is frequently aggressive and there is currently no general consensus regarding an effective treatment strategy. The present study reports a case in which bortezomib combined with dexamethasone was used to treat refractory AITL. A 63‑year‑old woman was admitted to Sir Run Run Shaw Hospital, Zhejiang University School of Medicine (Zhejiang, China) on August 17, 2013. The patient had been diagnosed with AITL for 4 months and had experienced a relapse of symptoms for the 4 days prior to admission. The patient demonstrated fever and dyspnea, accompanied by severe edema in the face and lower limbs, which later spread to the right upper limb. The patient was treated with bortezomib plus dexamethasone, which rapidly relieved the symptoms. The patient was subsequently administered an additional 2 cycles of bortezomib‑based chemotherapy and survived for an additional 4 months, prior to succumbing to the disease. Only a small number of studies have reported the use of bortezomib in the treatment of T‑cell lymphoma. The present study suggested that bortezomib‑based treatment may be a reliable, safe and effective alternative for the treatment of relapsed/refractory PTCL. The efficacy of bortezomib as a treatment for PTCL requires additional evaluation in future studies.

View Figures

View References

1	Armitage JO: The aggressive peripheral T-cell lymphomas: 2013. Am J Hematol. 88:910–918. 2013. View Article : Google Scholar : PubMed/NCBI
2	Abouyabis AN, Shenoy PJ, Lechowicz MJ and Flowers CR: Incidence and outcomes of the peripheral T-cell lymphoma subtypes in the United States. Leuk Lymphoma. 49:2099–2107. 2008. View Article : Google Scholar : PubMed/NCBI
3	Anderson JR, Armitage JO and Weisenburger DD: Epidemiology of the non-Hodgkin's lymphomas: Distributions of the major subtypes differ by geographic locations. Non-Hodgkin's Lymphoma Classification Project. Ann Oncol. 9:717–720. 1998. View Article : Google Scholar : PubMed/NCBI
4	Phillips AA, Owens C, Lee S and Bhagat G: An update on the management of peripheral T-cell lymphoma and emerging treatment options. J Blood Med. 2:119–129. 2011. View Article : Google Scholar : PubMed/NCBI
5	Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J and Vardiman JW: WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. 2:(4th). Lyon: IARC. 2008.
6	Vose J, Armitage J and Weisenburger D: International T-Cell Lymphoma Project: International peripheral T-cell and natural killer/T-cell lymphoma study: Pathology findings and clinical outcomes. J Clin Oncol. 26:4124–4130. 2008. View Article : Google Scholar : PubMed/NCBI
7	Lister TA, Crowther D, Sutcliffe SB, Glatstein E, Canellos GP, Young RC, Rosenberg SA, Coltman CA and Tubiana M: Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: Cotswolds meeting. J Clin Oncol. 7:1630–1636. 1989.PubMed/NCBI
8	The International Non-Hodgkin's Lymphoma Prognostic Factors Project: A predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med. 329:987–994. 1993. View Article : Google Scholar : PubMed/NCBI
9	de Leval L, Gisselbrecht C and Gaulard P: Advances in the understanding and management of angioimmunoblastic T-cell lymphoma. Br J Haematol. 148:673–689. 2010. View Article : Google Scholar : PubMed/NCBI
10	Mourad N, Mounier N, Brière J, Raffoux E, Delmer A, Feller A, Meijer CJ, Emile JF, Bouabdallah R, Bosly A, et al: Clinical, biologic, and pathologic features in 157 patients with angioimmunoblastic T-cell lymphoma treated within the Groupe d'Etude des Lymphomes de l'Adulte (GELA) trials. Blood. 111:4463–4470. 2008. View Article : Google Scholar : PubMed/NCBI
11	Weisenburger DD, Savage KJ, Harris NL, Gascoyne RD, Jaffe ES, MacLennan KA, Rüdiger T, Pileri S, Nakamura S, Nathwani B, et al: International Peripheral T-cell Lymphoma Project: Peripheral T-cell lymphoma, not otherwise specified: A report of 340 cases from the International Peripheral T-cell Lymphoma Project. Blood. 117:3402–3408. 2011. View Article : Google Scholar : PubMed/NCBI
12	Federico M, Rudiger T, Bellei M, Nathwani BN, Luminari S, Coiffier B, Harris NL, Jaffe ES, Pileri SA, Savage KJ, et al: Clinicopathologic characteristics of angioimmunoblastic T-cell lymphoma: Analysis of the international peripheral T-cell lymphoma project. J Clin Oncol. 31:240–246. 2013. View Article : Google Scholar : PubMed/NCBI
13	Coiffier B, Brousse N, Peuchmaur M, Berger F, Gisselbrecht C, Bryon PA and Diebold J: Peripheral T-cell lymphomas have a worse prognosis than B-cell lymphomas: A prospective study of 361 immunophenotyped patients treated with the LNH-84 regimen. The GELA (Groupe d'Etude des Lymphomes Agressives). Ann Oncol. 1:45–50. 1990.PubMed/NCBI
14	Lunning MA: Treatment of peripheral T-cell lymphoma: Many shades of gray. Oncology (Williston Park). 29:545–550. 2015.PubMed/NCBI
15	Kyle RA and Rajkumar SV: Multiple myeloma. Blood. 111:2962–2972. 2008. View Article : Google Scholar : PubMed/NCBI
16	Richardson PG, Barlogie B, Berenson J, Singhal S, Jagannath S, Irwin D, Rajkumar SV, Srkalovic G, Alsina M, Alexanian R, et al: A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med. 348:2609–2617. 2003. View Article : Google Scholar : PubMed/NCBI
17	Goy A, Bernstein SH, Kahl BS, Djulbegovic B, Robertson MJ, de Vos S, Epner E, Krishnan A, Leonard JP, Lonial S, et al: Bortezomib in patients with relapsed or refractory mantle cell lymphoma: Updated time-to-event analyses of the multicenter phase 2 PINNACLE study. Ann Oncol. 20:520–525. 2009. View Article : Google Scholar : PubMed/NCBI
18	Liu S, Yuan Z, Zhang C, Fu W and Hou J: Bortezomib-based treatment for relapsed and refractory angioimmunoblastic T-cell lymphoma: Case report and literature review. Oncol Lett. 4:262–264. 2012.PubMed/NCBI
19	Hourigan CS, Forde PM, Ambinder RF and Gladstone DE: Bortezomib salvage therapy in refractory acute adult T-cell leukemia/lymphoma. Leuk Lymphoma. 54:2563–2564. 2013. View Article : Google Scholar : PubMed/NCBI
20	Wilson WH, Bryant G, Bates S, Fojo A, Wittes RE, Steinberg SM, Kohler DR, Jaffe ES, Herdt J, Cheson BD, et al: EPOCH chemotherapy: Toxicity and efficacy in relapsed and refractory non-Hodgkin's lymphoma. J Clin Oncol. 11:1573–1582. 1993.PubMed/NCBI
21	Kim SJ, Yoon DH, Kang HJ, Kim JS, Park SK, Kim HJ, Lee J, Ryoo BY, Ko YH, Huh J, et al: Consortium for Improving Survival of Lymphoma (CISL) investigators: Bortezomib in combination with CHOP as first-line treatment for patients with stage III/IV peripheral T-cell lymphomas: A multicentre, single-arm, phase 2 trial. Eur J Cancer. 48:3223–3231. 2012. View Article : Google Scholar : PubMed/NCBI
22	Lee J, Suh C, Kang HJ, Ryoo BY, Huh J, Ko YH, Eom HS, Kim K, Park K and Kim WS: Phase I study of proteasome inhibitor bortezomib plus CHOP in patients with advanced, aggressive T-cell or NK/T-cell lymphoma. Ann Oncol. 19:2079–2083. 2008. View Article : Google Scholar : PubMed/NCBI
23	Zinzani PL, Musuraca G, Tani M, Stefoni V, Marchi E, Fina M, Pellegrini C, Alinari L, Derenzini E, de Vivo A, et al: Phase II trial of proteasome inhibitor bortezomib in patients with relapsed or refractory cutaneous T-cell lymphoma. J Clin Oncol. 25:4293–4297. 2007. View Article : Google Scholar : PubMed/NCBI
24	Chen D, Frezza M, Schmitt S, Kanwar J and Dou QP: Bortezomib as the first proteasome inhibitor anticancer drug: Current status and future perspectives. Curr Cancer Drug Targets. 11:239–253. 2011. View Article : Google Scholar : PubMed/NCBI
25	Ri M, Iida S, Ishida T, Ito A, Yano H, Inagaki A, Ding J, Kusumoto S, Komatsu H, Utsunomiya A and Ueda R: Bortezomib-induced apoptosis in mature T-cell lymphoma cells partially depends on upregulation of Noxa and functional repression of Mcl-1. Cancer Sci. 100:341–348. 2009. View Article : Google Scholar : PubMed/NCBI
26	Shen L, Au WY, Guo T, Wong KY, Wong ML, Tsuchiyama J, Yuen PW, Kwong YL, Liang RH and Srivastava G: Proteasome inhibitor bortezomib-induced apoptosis in natural killer (NK)-cell leukemia and lymphoma: An in vitro and in vivo preclinical evaluation. Blood. 110:469–470. 2007. View Article : Google Scholar : PubMed/NCBI
27	Iwata S, Yano S, Ito Y, Ushijima Y, Gotoh K, Kawada J, Fujiwara S, Sugimoto K, Isobe Y, Nishiyama Y and Kimura H: Bortezomib induces apoptosis in T lymphoma cells and natural killer lymphoma cells independent of Epstein-Barr virus infection. Int J Cancer. 129:2263–2273. 2011. View Article : Google Scholar : PubMed/NCBI
28	Rice TW, Rodriguez RM and Light RW: The superior vena cava syndrome: Clinical characteristics and evolving etiology. Medicine (Baltimore). 85:37–42. 2006. View Article : Google Scholar : PubMed/NCBI
29	Yellin A, Rosen A, Reichert N and Lieberman Y: Superior vena cava syndrome. The myth - the facts. Am Rev Respir Dis. 141:1114–1118. 1990. View Article : Google Scholar : PubMed/NCBI
30	Chee CE, Bjarnason H and Prasad A: Superior vena cava syndrome: An increasingly frequent complication of cardiac procedures. Nat Clin Pract Cardiovasc Med. 4:226–230. 2007. View Article : Google Scholar : PubMed/NCBI